Tevogen Bio CEO Emphasizes Dedication to Equity Capital Retention and Long-Term Vision

The Importance of Preserving Equity for Shareholders in Biotech Financing Ryan Saadi’s Commitment to Efficient and Profit-Focused Strategies WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) — Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, reaffirms his commitment to preserving…

Read More

Get Ready for April’s Most Exciting Crypto Events: Unveiling What’s in Store!

April’s Most Anticipated Crypto Events Revealed The Exciting Month Ahead April 2024 is an important month in the growth and development of the world of cryptocurrencies. A series of significant events lined up on the horizon, starting from the highly anticipated Bitcoin halving to important legal proceedings involving big crypto firms and their once CEOs,…

Read More

“Boost Your Portfolio’s Defense with These Top 3 Stocks Amidst Consumer Confidence Dips and Rate Cut Uncertainty”

Why Consumer Staples Stocks are a Safe Bet During Market Volatility Introduction Consumer staples stocks are known for their stability and reliability, making them a safe bet for investors during times of market volatility. Companies in this sector produce essential products that consumers need on a daily basis, such as food, beverages, household goods, and…

Read More

Uncovering the Truth: Tingo Group’s Response to Short Seller’s Allegations

Uncovering the Truth: Tingo Group’s Response to Short Seller’s Allegations MONTVALE, N.J., Sept. 01, 2023 (GLOBE NEWSWIRE) — Tingo Group, Inc. (NASDAQ: TIO) (“Tingo” or the “Company”), a profitable and fast growing fintech, agri-fintech and food company, today issues a response to further allegations made by short seller Hindenburg Research (“Hindenburg”) on August 31, 2023….

Read More

Breaking News: Intercept Reapplies for FDA Approval of Obeticholic Acid for Liver Fibrosis in NASH Patients

Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis NDA supported by robust NASH clinical development program Two positive interim analyses from the Phase 3 REGENERATE study NDA includes detailed safety analysis of 2,477 patients with nearly 1,000 patients on study drug for 4 years MORRISTOWN, N.J., Dec….

Read More